The WT is genetically heterogeneous disease in which somatic changes include mutations in Wilms tumor 1 (WT1) (10–20%), catenin beta 1 (CTNNB1) (15%), Wilms tumor gene on the X chromosome protein (WTX) (15–20%), tumor protein P53 (TP53) (70% of anaplastic tumors) (Park et al., 1993; Koesters et al., 1999; Rivera et al., 2007; Maschietto et al., 2014), and imprinting control region that controls expression of insulin-like growth factor 2 gene and adjacent H19 (37% of tumors) (Scott et al., 2012). Here, TP53 is linked to neoplasm.